Samrat Pharmachem Limited (BOM:530125)

Market Cap	1.15B
Revenue (ttm)	2.86B
Net Income (ttm)	71.12M
Shares Out	3.09M
EPS (ttm)	23.02
PE Ratio	16.10
Forward PE	n/a
Dividend	1.00 (0.27%)
Ex-Dividend Date	Sep 18, 2025

Volume	1,113
Average Volume	3,713
Open	361.05
Previous Close	365.40
Day's Range	361.00 - 379.70
52-Week Range	302.05 - 646.00
Beta	-0.19
RSI	54.09
Earnings Date	Aug 13, 2025

About Samrat Pharmachem

Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodic acid, iodine, iodine monochloride, iodoquinol, lithium iodide, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate, potassium iodide, potassium metaper iodate, povidone iodine, selenium dioxide, sodium iodate, sodium iodide, sodium metaper iodate, sodium...

• Industry: Industrial Inorganic Chemicals
• Founded: 1992
• Employees: 32
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530125

Financial Performance

In 2024, Samrat Pharmachem's revenue was 2.86 billion, an increase of 1.50% compared to the previous year's 2.82 billion. Earnings were 71.12 million, an increase of 228.87%.